3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Follicular
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Advanced Liver Cancers
1
Interventions
Paclitaxel
12
atezolizumab
11
Gemcitabine
9
pembrolizumab
8
Injections
6
Carboplatin
6
Irinotecan
5
Docetaxel
5
Cetuximab
5
tocilizumab
4
navitoclax
4
Leucovorin
4
Fluorouracil
4
Bevacizumab
4
olaparib
3
cobimetinib
3
Oxaliplatin
3
Nivolumab
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
tivozanib
2
tislelizumab
2
spartalizumab
2
ridaforolimus
2
plocabulin
2
obinutuzumab
2
motesanib diphosphate
2
liposomal doxorubicin
2
linifanib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumors
×
Tiragolumab
×
Clear all
NCT06331598
2024-12-24
IMperator
Hoffmann-La Roche
Phase 2
Withdrawn